Saturday 17 October 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
59.24
1.75
−2.87%
Follow PTCT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.64 |
Piotroski F-Score |
3 | 3 | 3 | 3 | 2 | 3 | 2 | 3 | 3 | 7 |
Altman Z-Score |
(2.70) | (0.78) | 0.13 | 0.72 | 0.41 | (0.73) | (1.63) | (1.85) | (1.81) | 1.86 |
P/S ratio |
4.62 | 3.52 | 6.04 | 9.21 | 10.58 | 5.21 | 3.92 | 2.24 | 4.30 | 3.49 |
Altman Z″-Score (non-manufacturers) |
(6.20) | (4.38) | (2.05) | (0.59) | (0.59) | (3.32) | (5.91) | (5.39) | (5.56) | 1.56 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.62 |
Beneish M-Score |
(1.56) | 56.43 | (1.74) | (3.23) | (3.09) | (2.66) | (2.72) | (3.81) | (3.43) | (1.48) |
P/Operating CF |
(28.70) | 32.14 | (105.56) | (277.01) | (62.61) | (40.77) | (16.49) | (20.92) | (115.61) | (176.27) |
P/B ratio |
3.20 | 4.37 | 4.56 | 4.76 | 8.36 | 1,951.79 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
3.20 | 29.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.01 | 3.28 | 5.76 | 8.00 | 10.34 | 5.98 | 5.26 | 3.56 | 5.84 | 3.87 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 229.19 | 0.00 | 7.53 |
EV/Operating CF |
(2.41) | (63.41) | (55.13) | (24.88) | (20.29) | (12.81) | (10.30) | (21.07) | (43.75) | 9.41 |
EV/FCF |
(2.36) | (48.47) | (43.87) | (16.52) | (14.43) | (8.86) | (7.22) | (10.25) | (20.35) | 15.10 |
Quick Ratio |
5.17 | 2.82 | 1.77 | 3.15 | 4.23 | 1.74 | 1.39 | 1.72 | 2.23 | 2.20 |
Current Ratio |
5.27 | 3.04 | 1.92 | 3.30 | 4.44 | 1.87 | 1.71 | 2.02 | 2.35 | 2.35 |
Net Debt/EBITDA |
1.05 | 1.01 | 0.83 | 1.77 | 0.27 | (1.36) | (3.33) | 85.07 | (15.80) | 0.73 |
Debt/Assets |
36.46% | 37.02% | 13.67% | 19.33% | 45.83% | 61.17% | 79.05% | 111.59% | 139.75% | 89.62% |
Debt/Equity |
0.82 | 0.93 | 0.44 | 0.53 | 2.10 | 824.39 | (3.88) | (2.58) | (2.17) | (12.65) |
Asset Turnover |
0.26 | 0.59 | 0.35 | 0.22 | 0.20 | 0.26 | 0.38 | 0.52 | 0.45 | 0.75 |
Operating CF/Net income |
0.73 | 0.13 | 0.22 | 0.39 | 0.44 | 0.48 | 0.64 | 0.25 | 0.30 | 1.04 |
Capex/Depreciation |
(0.32) | (4.30) | (0.59) | (1.47) | (0.65) | (1.20) | (0.92) | (0.27) | (0.21) | (0.40) |
Interest Coverage |
(15.96) | (5.32) | (9.21) | (19.31) | (7.66) | (4.35) | (4.92) | (3.40) | (1.81) | 5.69 |
| (82.24%) | (57.24%) | (50.51%) | (53.24%) | (81.42%) | (216.75%) | 323.46% | 107.51% | 37.91% | (104.75%) | |
| (44.79%) | (23.90%) | (16.95%) | (18.34%) | (22.87%) | (25.27%) | (30.68%) | (34.80%) | (20.18%) | 29.66% | |
ROIC |
0.00% | (36.48%) | (26.18%) | (68.01%) | (69.14%) | (56.59%) | (47.36%) | (65.37%) | (130.42%) | 121.13% |
Return on Tangible Assets |
(64.86%) | (45.04%) | (76.81%) | (44.53%) | (44.34%) | (105.28%) | (155.22%) | (89.18%) | (42.97%) | 50.16% |
Average Days of Receivables |
110.02 | 75.85 | 93.63 | 66.03 | 67.03 | 74.85 | 81.28 | 62.59 | 71.73 | 38.30 |
Research and Development Expense of Revenue |
142.23% | 60.42% | 64.96% | 83.87% | 125.44% | 100.39% | 93.23% | 71.08% | 66.25% | 26.31% |
Selling, General and Administrative Expense of Revenue |
117.44% | 62.38% | 58.00% | 65.98% | 64.39% | 53.06% | 46.65% | 35.46% | 37.30% | 20.06% |
Intangible Assets out of Total Assets |
0.00 | 0.34 | 0.70 | 0.49 | 0.36 | 0.42 | 0.46 | 0.24 | 0.12 | 0.16 |
Share Based Compensation of Revenue |
42.33% | 15.72% | 12.56% | 13.73% | 18.47% | 19.22% | 15.79% | 10.84% | 9.25% | 4.31% |
Graham Net Nets |
0.29 | 0.02 | (0.28) | (0.09) | (0.12) | (0.35) | (0.50) | (0.71) | (0.41) | (0.14) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.12 | 45.36 | 39.00 | 0.00 |
Earnings Yield |
(37.13%) | (11.91%) | (7.84%) | (9.31%) | (10.98%) | (18.65%) | (20.41%) | (29.81%) | (10.48%) | 11.57% |
Free Cash Flow Yield |
(27.55%) | (1.92%) | (2.17%) | (5.26%) | (6.77%) | (12.95%) | (18.60%) | (15.51%) | (6.67%) | 7.34% |
Revenue per Share |
2.43 | 4.96 | 5.68 | 5.22 | 5.77 | 7.64 | 9.74 | 12.53 | 10.50 | 21.76 |
Operating CF per Share |
(3.04) | (0.26) | (0.59) | (1.68) | (2.94) | (3.57) | (4.97) | (2.12) | (1.40) | 8.94 |
Capex per Share |
(0.05) | (2.05) | (0.33) | (0.77) | (0.85) | (1.21) | (2.13) | (1.61) | (0.60) | (0.11) |
Free Cash Flow per Share |
(3.09) | (2.31) | (0.93) | (2.45) | (3.79) | (4.78) | (7.10) | (3.73) | (2.00) | 8.83 |
Cash per Share |
6.80 | 4.88 | 4.89 | 11.66 | 16.71 | 10.98 | 5.73 | 11.72 | 14.83 | 24.46 |
Shareholders Equity per Share |
3.51 | 3.99 | 7.53 | 10.10 | 7.30 | 0.02 | (4.84) | (10.94) | (14.29) | (2.58) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.51 | 3.99 | 7.53 | 10.10 | 7.30 | 0.02 | (4.84) | (10.94) | (14.29) | (2.58) |
Free Cash Flow |
(105.34) | (90.33) | (43.17) | (144.08) | (250.05) | (336.66) | (509.11) | (279.04) | (153.88) | 702.41 |
Working Capital |
211.66 | 167.02 | 154.06 | 543.43 | 954.41 | 445.02 | 287.55 | 615.53 | 784.55 | 1,305.52 |
Capital Expenditures |
(1.78) | (80.26) | (15.53) | (45.44) | (55.98) | (85.33) | (152.46) | (120.62) | (46.19) | (8.79) |
Net Current Asset Value |
111.52 | 13.85 | (447.64) | (250.17) | (494.55) | (982.25) | (1,358.92) | (1,495.62) | (1,437.56) | (830.13) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.72 |
Capex to Sales |
0.02 | 0.41 | 0.06 | 0.15 | 0.15 | 0.16 | 0.22 | 0.13 | 0.06 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.97 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.74 | 2.23 | 2.06 | 1.44 | 2.55 | 1.36 | 2.28 | 5.21 | 3.67 | 0.40 |
Cash ROIC |
(23.44%) | (18.33%) | (5.90%) | (9.03%) | (9.63%) | (17.17%) | (36.06%) | (12.84%) | (6.35%) | 16.19% |
Accounts Receivable Turnover |
4.59 | 5.95 | 4.89 | 4.97 | 6.07 | 5.97 | 5.25 | 5.93 | 5.05 | 10.18 |
Accounts Payable Turnover |
0.00 | 0.07 | 0.12 | 0.08 | 0.09 | 0.12 | 0.15 | 0.18 | 0.16 | 0.14 |
Inventory Turnover |
— | 0.34 | 0.94 | 0.69 | 1.00 | 1.87 | 2.37 | 2.50 | 2.13 | 0.91 |
Average Days of Payables |
0.00 | 6,096.31 | 3,693.18 | 4,790.75 | 4,666.42 | 3,260.52 | 2,617.25 | 2,184.80 | 1,935.03 | 2,960.12 |
Days of Inventory on Hand |
— | 857.59 | 464.30 | 580.06 | 360.28 | 179.02 | 178.16 | 170.43 | 147.49 | 618.36 |
Average Receivables |
18.01 | 32.66 | 54.15 | 61.72 | 62.73 | 90.19 | 133.03 | 158.22 | 159.69 | 170.09 |
Average Payables |
47.00 | 62.60 | 102.32 | 143.74 | 200.72 | 265.48 | 304.58 | 356.17 | 348.14 | 342.78 |
Average Inventory |
— | 13.50 | 13.44 | 17.70 | 18.99 | 17.28 | 18.83 | 26.19 | 26.89 | 51.42 |
Average Assets |
317.31 | 330.50 | 755.44 | 1,371.50 | 1,916.03 | 2,073.17 | 1,821.84 | 1,800.66 | 1,800.36 | 2,301.90 |
Average Common Equity |
172.79 | 138.01 | 253.58 | 472.53 | 538.16 | 241.71 | (172.82) | (582.82) | (958.31) | (651.69) |
Columns are period end dates